Renovaro BioSciences, Amsterdam UMC enter collaboration agreement

Renovaro agreed on terms for an exclusive collaboration agreement with Amsterdam University Medical Center to jointly evaluate and develop blood platelet RNA diagnostics. This partnership marks an important step forward in the clinical validation and advancement of a promising new approach to disease detection and monitoring. The collaboration will focus on assessing the clinical utility of blood platelet RNA signatures as a powerful biomarker source. This effort will leverage the unique Artificial Intelligence/Machine Learning capabilities of Renovaro as well as the newly announced compute resources provided through their agreement with Nebul, to uncover subtle disease-specific signals from blood samples and is aimed at transforming diagnostic and prognostic approaches across multiple cancer types. Under the terms of the agreement, Renovaro and Amsterdam UMC will work together to refine and improve predictive performance, aiming for a high degree of clinical accuracy. The project will involve collection and analysis of blood samples, data integration from multiple modalities, and the development of sophisticated deep learning models.